Date and Time
November 14, 2007
1:30 PM - 3:00 PM

Availability
Open to the public
No RSVP required

Speaker
Katherine E. Herz - CHP/PCOR Trainee at Stanford University

Malaria causes an estimated 300-500 million episodes of illness per year, killing 1-3 million people annually. An estimated 90% of malaria deaths occur in sub-Saharan Africa, over 75% among children, the vast majority of whom are younger than 5 years of age. Over the past two decades, resistance to conventional anti-malarial medications has become widespread.

In 2006, the World Health Organization changed its treatment recommendation, declaring new, artemisinin-based combination therapies (ACTs) the treatment of choice in sub-Saharan Africa. The ACTs are much more expensive than conventional antimalarials, however, and affordability concerns have limited the use of ACTs in Africa. This study uses clinical data from Uganda, a country with areas of markedly different malarial risk, to examine the cost-effectiveness of both conventional and newer combination treatments for uncomplicated malaria.